Introduction
============

Breast cancer has been confirmed by gene expression analysis to be a heterogeneous disease ([@b1-mco-0-0-1511],[@b2-mco-0-0-1511]) that may be divided into biologically distinct subtypes. In clinical practice, the cancer subtype is determined using immunohistochemistry ([@b3-mco-0-0-1511],[@b4-mco-0-0-1511]) and a therapeutic plan is designed according to the subtype ([@b5-mco-0-0-1511]). Lung metastasis is commonly observed in breast cancer patients at the time of relapse. Patients with metastatic disease have median survival times of 12--24 months ([@b6-mco-0-0-1511],[@b7-mco-0-0-1511]). The majority of patients with breast cancer metastases to the lungs are treated with systemic therapy. However, lung nodules that develop in breast cancer patients during follow-up after curative breast surgery may not always represent metastatic lesions. Therefore, the final treatment strategy for breast cancer patients with lung nodules depends on the pathological diagnosis of the nodules. However, it is difficult to obtain an accurate diagnosis only by using imaging modalities, such as computed tomography (CT), particularly in patients with solitary nodules. For a definitive diagnosis of the lung lesions, tumor biopsy, such as transbronchial or CT-guided biopsy, may be performed. Video-assisted thoracoscopic surgery (VATS) with intraoperative inspection is an optimal procedure for the complete removal of the lesions and for reaching a definitive diagnosis, but the survival benefit of total biopsy of lung nodules by VATS remains to be established.

The aim of the present study was to evaluate the significance of lung biopsy, including total biopsy by VATS, in breast cancer patients who develop lung nodules during follow-up after curative breast surgery.

Patients and methods
====================

### Patients

In total, 53 consecutive patients who underwent lung biopsy following curative surgery for breast cancer in two institutions (Hiroshima University Hospital and Hiroshima Prefectural Hospital, Hiroshima, Japan) between 1995 and 2014 were enrolled in this retrospective study. The age at lung biopsy was 27--84 years (mean, 63 years). A total of 30 patients (57%) had a solitary lung nodule, 9 (17%) had 2 nodules, and 14 (26%) had ≥3 nodules. VATS was performed in 45 patients, transbronchial lung biopsy in 7 patients, and CT-guided biopsy in 1 patient. The indications for lung biopsy included lung nodules that were difficult to diagnose clinically, and those for which the treatment strategy would depend on the pathological diagnosis.

In the event of malignant lung tumors, a non-curative lung biopsy was defined as a macroscopically visible incomplete resection. When lung biopsy was performed in patients with metastatic disease at extrapulmonary sites, the procedure was also non-curative.

The majority of the patients who were included in the present study underwent curative surgery for primary breast cancer at one of the two aforementioned institutions and they were subsequently followed up. The clinical records and pathological reports of patients who underwent surgery for primary breast cancer at other hospitals and presented to our hospital with lung nodules were obtained from the respective hospitals. Use of these data was approved by the Institutional Review Board (H27-073).

Patients were divided into the metastasis (patients with metastatic lung cancer from breast cancer; n=25) and others (patients with other pathologies; n=28) groups. In the present study, we focused on the survival benefits of lung biopsy in the metastasis group compared with the others group with variable backgrounds, as the number of patients with primary lung cancer or benign lung tumors was limited. Various clinicopathological factors recorded at the time of primary breast cancer surgery were compared between the groups, and a subgroup analysis was performed in the metastasis group to compare their outcomes after lung biopsy.

### Histological assessment

Routine hematoxylin and eosin staining was performed on sections from tumor specimens in order to determine the histological tumor type. Nuclear grade was determined according to the 17th edition of the general rules for clinical and pathological recording of breast cancer of the Japanese Breast Cancer Society ([@b8-mco-0-0-1511]). Immunohistochemical staining was performed to evaluate the expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67, as previously described ([@b9-mco-0-0-1511]). The following monoclonal antibodies were used in the analysis: ER (SP1; 790--4324, prediluted, Ventana Medical Systems, Tucson, AZ, USA); PR (1E2; 790--2223, prediluted, Ventana Medical Systems); Ki-67 (MIB-1; M7240, 1:80 dilution, DAKO, Glostrup, Denmark); and HER2 (4B5; 790--2991, prediluted, Ventana Medical Systems). Based on the expression of ER, PR, HER2 and Ki-67, patients were classified as having one of the following subtypes, as previously described ([@b9-mco-0-0-1511]): Luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-positive and triple-negative types.

### Statistical analysis

Data are presented as number (%) or as mean, unless otherwise stated. Categorical variables in both groups were compared using Pearson\'s Chi-squared test, and small samples were assessed using Fisher\'s exact test.

The overall survival (OS) in the metastasis group was calculated from the date of lung biopsy to the date of death from any cause, or the date of the last follow-up. The Kaplan-Meier method was used to calculate OS, and patient subgroups were compared using the log-rank test. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University: <http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html>; Kanda, 2012), which is a graphical user interface for R statistical software, version 2.13.0 (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of the R commander (version 1.6--3) that was designed to include statistical functions frequently used in biostatistics ([@b10-mco-0-0-1511]).

Results
=======

### Characteristics of primary breast cancer patients with lung nodules

All patients who underwent lung biopsy had no major fatal complications, although there were a few minor complications, such as air leakage caused by the biopsy of peripheral lung nodules. The pathological diagnoses of the lung nodules included breast cancer metastases to the lungs in 25 (47%), primary malignant lung tumor in 21 (40%) and benign disease in 7 patients (13%). Of the 21 patients with primary malignant lung tumors, 17 had adenocarcinoma, 2 had large-cell carcinoma, 1 had small-cell carcinoma and 1 had a carcinoid tumor. Of the 7 patients with benign disease, 4 had inflammation, 2 had organizing pneumonia and 1 had a hamartoma. Of the 25 patients with breast cancer metastases to the lungs, curative lung biopsy was performed in 14 patients (56%). Of the 21 patients with primary malignant lung tumors, 18 (86%) had stage I disease and 19 (90%) underwent curative lung biopsy ([Fig. 1](#f1-mco-0-0-1511){ref-type="fig"}).

The comparison of the clinical factors between the metastasis and the others groups at the time of primary breast surgery by univariate analysis revealed that the patients in the metastasis group were significantly younger compared with those in the others group (median age, 59 vs. 65 years, respectively; P\<0.001). The rate of premenopausal status was significantly higher in the metastasis group compared with that in the others group (56 vs. 14%, respectively; P=0.003). The patients in the metastasis group had higher node-positive rates compared with those in the others group (56 vs. 11%, respectively; P=0.001). The clinical stage of the patients in the metastasis group was also higher compared with that in the others group (P=0.027). Therefore, mastectomy (64 vs. 18%, respectively; P\<0.001) and axillary lymph node dissection (96 vs. 32%, respectively; P\<0.001) were performed more frequently in the metastasis group compared with the others group. Postoperative radiotherapy and primary systemic chemotherapy were administered more frequently in the metastasis group compared with the others group (56 vs. 18%, P=0.005 and 80 vs. 32%, P\<0.001, respectively;). The clinicopathological characteristics of the patients are summarized in [Tables I](#tI-mco-0-0-1511){ref-type="table"} and [II](#tII-mco-0-0-1511){ref-type="table"}.

The comparison of the pathological factors between the groups at the time of primary breast surgery by univariate analyses revealed that the patients in the metastasis group had higher node-positive rates compared with those in the others group (79 vs. 52%, respectively; P=0.0492). The rate of positive lymphovascular invasion was significantly higher in the metastasis group compared with that in the others group (52 vs. 25%, respectively; P=0.004).

The mean disease-free interval from the surgery for primary breast cancer to lung biopsy, multiplicity of lung nodules, and curability by lung biopsy did not differ significantly between the two groups ([Table III](#tIII-mco-0-0-1511){ref-type="table"}).

Multivariate analysis revealed that mastectomy (P\<0.001) and axillary resection (P\<0.001) were independent factors predicting whether the lung nodules would be metastases from breast cancer ([Table I](#tI-mco-0-0-1511){ref-type="table"}).

### Survival analysis

In the metastasis group, 11 patients with solitary nodules had significantly better survival rates compared with 14 patients with multiple nodules (3-year survival rates, 100 vs. 74.3%, respectively; P=0.00104; [Fig. 2](#f2-mco-0-0-1511){ref-type="fig"}). Moreover, 14 patients who underwent curative lung biopsy had significantly higher survival rates compared with 11 patients who underwent non-curative biopsy (3-year survival rates, 89 vs. 81%, respectively; P=0.00673; [Fig. 3](#f3-mco-0-0-1511){ref-type="fig"}).

### Discordance in subtype between the primary tumor and metastases

A total of 17 patients with metastases maintained the same tumor phenotype as the primary tumor, whereas discordance of the ER, PR, HER2, or Ki-67 expression status was observed between the primary and metastatic tumors in 6 patients (24%). A total of 3 patients with ER or PR upregulation received endocrine therapy instead of chemotherapy following identification of discordance ([Table IV](#tIV-mco-0-0-1511){ref-type="table"}).

Discussion
==========

Although lung nodules may develop during the follow-up period in breast cancer patients, they are not necessarily metastases from the primary breast cancer but may correspond to other pathologies, such as primary lung cancer or benign lesions. The choice of treatment strategy largely depends on the pathology. In the event of pathologically confirmed lung metastasis, the phenotype of the tumor may be identified from the analysis of the specimens, in order to determine whether the phenotype of the metastatic lesion is in concordance or discordance with that of the primary lesion. If discordance is detected, the systemic therapy regimen must be selected accordingly. Thus, based on the advantages of a definitive pathological diagnosis for recurrent breast cancer, the international guidelines for breast cancer recommend a biopsy for recurrent lesions whenever possible ([@b11-mco-0-0-1511]).

Previous studies have demonstrated that patients with breast cancer are at high risk of developing secondary malignancies ([@b12-mco-0-0-1511]--[@b15-mco-0-0-1511]). In the present study, over half of the lung nodules that developed during the follow-up period after breast cancer surgery were not lung metastases from breast cancer, but comprised a variety of histological diagnoses, including 21 primary lung cancers. Jensen *et al* also reported that the biopsies from the suspicious metastatic lesions revealed benign disease or other malignancies in 14% of the patients ([@b16-mco-0-0-1511]), whereas Tanaka *et al* ([@b17-mco-0-0-1511]) demonstrated that 75% of the 52 patients who underwent surgery for lung nodules that developed during the follow-up period after breast cancer surgery had pathologically confirmed metastases from the primary breast cancer. In the present study, of the 53 patients with lung nodules, 47% of those who underwent lung biopsy had metastasis from the primary breast cancer. However, this proportion was lower compared with that reported in previous studies ([@b16-mco-0-0-1511],[@b17-mco-0-0-1511]). This may be attributed to the fact that the patients included in our cohort were highly selected, i.e., the indications for lung biopsy were restricted to only lung nodules with difficult clinical diagnoses. When the lung nodules were proven to be metastatic based on the clinical course and imaging findings, it was decided that there was no indication for lung biopsy, although this policy was not in accordance with the recommendations of the international guidelines published in 2015 ([@b11-mco-0-0-1511]).

Rena *et al* ([@b18-mco-0-0-1511]) demonstrated that there were no statistically significant differences between the radiological characteristics of lung nodules and the pathological profiles of the metastases from primary breast cancer, primary lung cancer, or benign tumors. The present study demonstrated that the patients in the metastasis group were younger compared with those in the others group, and the clinicopathological characteristics of the primary cancer in the metastasis group indicated more advanced disease compared with the others group. However, a definitive diagnosis of the lung nodules that develop during the follow-up period as metastases from the primary breast cancer is difficult to make based on the clinicopathological characteristics of the primary cancer alone.

The lack of evidence regarding any survival benefits conferred by surgical treatment of breast cancer metastases to the lung renders the procedure controversial. Fan *et al* ([@b19-mco-0-0-1511]) demonstrated in a meta-analysis that the pooled 5-year survival rate after lung metastasectomy in breast cancer patients was 46%. They also demonstrated the prognostic value of complete resection of metastases and solitary lung metastasis. The present study investigated the outcomes in patients with solitary metastases when surgical resection was performed as a total biopsy of the lung nodule. The survival benefits of metastasectomy should be further discussed, as there are no long-term data available and the number of cases in the present retrospective study was limited, with variable backgrounds.

Changes in the HER2 and hormone receptor status of metastatic foci from primary cancer may lead to the modification of treatment strategies based on the indications for HER2-targeted or endocrine therapies. Previous studies reported discordance rates of 10--40% for the hormone receptor status and 5--20% for the HER2 status ([@b20-mco-0-0-1511]--[@b22-mco-0-0-1511]). In the present study, the discordance rates for hormone receptor and HER2 status were 12 and 8%, respectively. Welter *et al* ([@b23-mco-0-0-1511]) demonstrated that the number of metastases, tumor stage at initial presentation, complete resection, and pleural/chest wall involvement were not prognostic factors of survival. Instead, ER expression predicted prolonged survival, with a 5-year survival rate of 76% for ER-positive and 12% for ER-negative tumors, whereas similar statistically significant differences were identified according to the HER2 expression status ([@b23-mco-0-0-1511]). The appropriate introduction of endocrine therapies may contribute to longer survival in the future.

Patients with other lung pathologies identified by biopsy may also benefit from lung biopsy. The majority of patients with primary malignant lung tumors confirmed by biopsy had early-stage disease and were able to undergo curative resection. This allows the circumvention of unnecessary systemic therapies for metastatic breast cancer. Patients with benign pathologies confirmed by biopsy may also benefit from lung biopsy.

In conclusion, the clinical diagnosis of lung nodules that developed during follow-up after curative breast surgery remains difficult, despite the current developments in imaging techniques. Although the clinicopathological profiles of primary breast cancers provide useful information regarding the differential diagnosis of lung nodules, lung biopsy is key to reaching a definitive diagnosis and designing the subsequent treatment strategy. Moreover, it may improve the prognosis when metastatic lung nodules from primary breast cancer are resected with curative intent.

![Histological diagnosis of lung nodules in breast cancer patients.](mco-08-02-0250-g00){#f1-mco-0-0-1511}

![Overall survival according to the number of lung metastases.](mco-08-02-0250-g01){#f2-mco-0-0-1511}

![Overall survival according to the resectability of lung metastases.](mco-08-02-0250-g02){#f3-mco-0-0-1511}

###### 

Clinical characteristics of primary breast cancer.

  Variables                                                    Metastasis (n=25)   Others (n=28)                                        P-value   Multivariate P-value
  ------------------------------------------------------------ ------------------- ---------------------------------------------------- --------- ----------------------
  Median age, years (range)                                    59 (25--63)         65 (41--78)                                          \<0.001   
  Menopausal status                                                                                                                     0.003     --
    Premenopausal/postmenopausal                               14/11               4/24                                                           
  BMI, kg/m^2^ (range)                                         22.4 (16.6--30.6)   23.6 (17.4--34.2)                                    0.232     
  Patients with other cancers                                                                                                           0.183     
    Yes/no                                                     22/3b               20/8^[c](#tfn2-mco-0-0-1511){ref-type="table-fn"}^             
  Contralateral breast cancer                                                                                                           0.113     
    Yes/no                                                     0/25                4/24                                                           
  Breast/ovarian cancer family history                                                                                                  0.404     
    Yes/no                                                     4/21                2/26                                                           
  Clinical tumor stage                                                                                                                  0.417     
    Tis/T1,2/T3,4                                              0/22/3              3/23/2                                                         
  Clinical node stage                                                                                                                   0.001     --
    Negative/positive                                          11/14               25/3                                                           
  Clinical stage                                                                                                                        0.027     
    0/I/II/III                                                 0/8/12/5            3/16/8/1                                                       
  Type of breast surgery                                                                                                                \<0.001   0.045
    Mastectomy/partial mastectomy                              16/9                5/23                                                           
  Axillary LN dissection                                                                                                                \<0.001   0.001
    None or SLNB/Ax                                            1/24                19/9                                                           
  Radiation therapy                                                                                                                     0.005     --
    Yes/no                                                     11/14               23/5                                                           
  Chemotherapy^[a](#tfn1-mco-0-0-1511){ref-type="table-fn"}^                                                                            \<0.001   --
    Yes/no/unknown                                             20/4/1              9/19/0                                                         
  Hormonal therapy                                                                                                                      0.321     
    Yes/no/unknown                                             13/11/1             19/9/0                                                         

Chemotherapy includes primary systemic chemotherapy. bThyroid, lung, stomach.

Ovary, esophagus, rectum, oral, pancreas, brain, duodenum, except for secondary lung cancer. BMI, body mass index; metastasis, breast cancer metastases; LN, lymph node; SLNB, sentinel lymph node biopsy; Ax, axillary lymph node dissection. The patient population was subdivided according to histological diagnosis of breast cancer metastases or others.

###### 

Pathological characteristics of primary breast cancer.

  Variables                         Metastasis (n=25)   Others (n=28)   P-value   Multivariate P-value
  --------------------------------- ------------------- --------------- --------- ----------------------
  Pathological tumor stage; (y)pT                                       0.229     
    Tis/T1,2/T3,4                   0/21/4              4/23/1                    
  Pathological node stage; (y)pN                                        0.0492    --
    Negative/positive               13/12               22/6                      
  Pathological stage                                                    0.101     
    0/I/II/III                      0/8/10/7            4/13/7/4                  
  Lymphovascular invasion                                               0.004     --
    Negative/positive/unknown       4/13/8              17/7/4                    
  Nuclear grade                                                         0.0552    
    1/2/3/unknown                   3/3/8/11            6/11/4/7                  
  ER status                                                                       
    Negative/positive/unknown       8/15/2              5/23/0          0.207     
  PR status                                                             0.167     
    Negative/positive/unknown       12/11/2             9/19/0                    
  HER2 status, n (%)                                                    0.092     
    0/1+/2+/3+/unknown              7/4/5/4/5           5/11/3/1/7                
  Ki-67                                                                           
    \<20%/\>20%/unknown             7/11/7              7/6/15          0.481     
  Tumor subtype, n (%)                                                  0.168     
    Luminal/non-luminal             16/7                21/3                      

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

###### 

Characteristics of patients with lung nodules.

  Variables                       Metastases (n=25)   Others (n=28)   P-value   Multivariate P-value
  ------------------------------- ------------------- --------------- --------- ----------------------
  Disease-free interval, months                                       0.325     
    Mean (SD)                     66.3 (45.5)         52.7 (53.8)               
  No. of lung nodules                                                 0.101     --
    Solitary/multiple             11/14               19/9                      
  Resection of metastases                                                       
    Curative/non-curative         14/11               22/6            0.139     --

SD, standard deviation.

###### 

Discordance in subtype between the primary tumor and metastases.

  Variables                                                      n=25 (%)   Patient status (n)
  ------------------------------- ------------------------------ ---------- --------------------
  Concordant phenotype                                           17 (68)    Alive (7)
                                                                            Deceased (10)
  Discordant phenotype            Change of HR, HER2 and Ki-67   6 (24)     Alive (4)
                                                                            Deceased (2)
    Luminal A → luminal B         Upregulation of Ki-67          1 (17)     Alive
    Luminal HER2 → luminal B      Loss of HER2                   2 (33)     Deceased
    Triple-negative → luminal B   Upregulation of ER and/or PR   3 (50)     Alive
  N/A phenotype                                                  2 (8)      Alive (1)
                                                                            Deceased (1)

HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; N/A, not available.
